Click Here to Chat on WhatsApp
+16312597728

(Get Answer)

Pembrolizumab Immunotherapy Agent Essay Discussion Paper

Question





Pembrolizumab is an immunotherapy agent that targets PD-L1 expression positivity greater than or equal to:







A. 40%

B. 50%

C. 60%

D. 75%








Expert Answer

This solution was written by a subject matter expert. It's designed to help students like you learn core concepts Pembrolizumab Immunotherapy Agent Essay Discussion Paper
ORDER YOUR PAPER NOW








Step-by-step


1st step
All steps
Answer only


Step 1/2








The correct answer is B. 50%. 







EXPLANATION



Pembrolizumab is an immunotherapy agent that targets PD-L1 expression positivity, and the threshold for its use may vary depending on the cancer type and stage. However, for certain types of cancer, such as non-small cell lung cancer, Pembrolizumab is indicated for patients whose tumors have a PD-L1 expression positivity of 50% or greater. Therefore, the correct answer is B. 50%.


















Step 2/2








Pembrolizumab is a monoclonal antibody that targets the programmed death receptor-1 (PD-1) pathway by binding to the PD-1 receptor and blocking its interaction with its ligands, PD-L1 and PD-L2. PD-L1 is expressed on the surface of tumor cells and other cells in the tumor microenvironment, and its interaction with PD-1 on T cells can suppress the immune response to the tumor. By blocking this interaction, Pembrolizumab can help activate the immune system to recognize and attack cancer cells.

The use of Pembrolizumab is primarily based on the expression of PD-L1 in the tumor tissue. The level of PD-L1 expression is typically reported as the percentage of tumor cells with staining for PD-L1 on immunohistochemistry (IHC) analysis. The threshold for PD-L1 expression positivity may vary depending on the cancer type and stage, as well as the specific diagnostic test used for PD-L1 assessment Pembrolizumab Immunotherapy Agent Essay Discussion Paper







EXPLANATION



For example, in patients with advanced non-small cell lung cancer (NSCLC) who have not received prior systemic therapy and have PD-L1 expression on at least 50% of tumor cells, Pembrolizumab is approved as a first-line treatment. Similarly, for patients with advanced urothelial carcinoma who are not eligible for cisplatin-based chemotherapy and have PD-L1 expression on at least 10% of tumor cells, Pembrolizumab is approved as a first-line treatment. In contrast, for patients with melanoma, Pembrolizumab is approved regardless of the level of PD-L1 expression.

ORDER  NOW

The use of Pembrolizumab is generally well-tolerated, with the most common side effects being fatigue, rash, and diarrhea. However, like all immunotherapies, it can cause immune-related adverse events (irAEs) that affect various organs and systems, such as the skin, gastrointestinal tract, liver, and endocrine glands. The management of irAEs usually involves the temporary or permanent discontinuation of Pembrolizumab and the administration of immunosuppressive drugs such as corticosteroids.









Final answer








Pembrolizumab is an immunotherapy agent that targets the PD-1/PD-L1 pathway and has shown efficacy in various types of cancer.

The correct answer is B. 50%
The decision to use Pembrolizumab depends on the level of PD-L1 expression in the tumor tissue and other clinical factors. While it has the potential to activate the immune system against cancer, it can also cause immune-related adverse events that require close monitoring and management Pembrolizumab Immunotherapy Agent Essay Discussion Paper

Expert Answer

Pembrolizumab Immunotherapy Agent Essay Discussion Paper

Question

Pembrolizumab is an immunotherapy agent that targets PD-L1 expression positivity greater than or equal to:
A. 40% B. 50% C. 60% D. 75%

Expert Answer

This solution was written by a subject matter expert. It's designed to help students like you learn core concepts Pembrolizumab Immunotherapy Agent Essay Discussion Paper

ORDER YOUR PAPER NOW

Step-by-step

Step 1/2
The correct answer is B. 50%.
EXPLANATION
Pembrolizumab is an immunotherapy agent that targets PD-L1 expression positivity, and the threshold for its use may vary depending on the cancer type and stage. However, for certain types of cancer, such as non-small cell lung cancer, Pembrolizumab is indicated for patients whose tumors have a PD-L1 expression positivity of 50% or greater. Therefore, the correct answer is B. 50%.
Step 2/2
Pembrolizumab is a monoclonal antibody that targets the programmed death receptor-1 (PD-1) pathway by binding to the PD-1 receptor and blocking its interaction with its ligands, PD-L1 and PD-L2. PD-L1 is expressed on the surface of tumor cells and other cells in the tumor microenvironment, and its interaction with PD-1 on T cells can suppress the immune response to the tumor. By blocking this interaction, Pembrolizumab can help activate the immune system to recognize and attack cancer cells.
The use of Pembrolizumab is primarily based on the expression of PD-L1 in the tumor tissue. The level of PD-L1 expression is typically reported as the percentage of tumor cells with staining for PD-L1 on immunohistochemistry (IHC) analysis. The threshold for PD-L1 expression positivity may vary depending on the cancer type and stage, as well as the specific diagnostic test used for PD-L1 assessment Pembrolizumab Immunotherapy Agent Essay Discussion Paper
EXPLANATION
For example, in patients with advanced non-small cell lung cancer (NSCLC) who have not received prior systemic therapy and have PD-L1 expression on at least 50% of tumor cells, Pembrolizumab is approved as a first-line treatment. Similarly, for patients with advanced urothelial carcinoma who are not eligible for cisplatin-based chemotherapy and have PD-L1 expression on at least 10% of tumor cells, Pembrolizumab is approved as a first-line treatment. In contrast, for patients with melanoma, Pembrolizumab is approved regardless of the level of PD-L1 expression.
The use of Pembrolizumab is generally well-tolerated, with the most common side effects being fatigue, rash, and diarrhea. However, like all immunotherapies, it can cause immune-related adverse events (irAEs) that affect various organs and systems, such as the skin, gastrointestinal tract, liver, and endocrine glands. The management of irAEs usually involves the temporary or permanent discontinuation of Pembrolizumab and the administration of immunosuppressive drugs such as corticosteroids.
Final answer
Pembrolizumab is an immunotherapy agent that targets the PD-1/PD-L1 pathway and has shown efficacy in various types of cancer.
The correct answer is B. 50%
The decision to use Pembrolizumab depends on the level of PD-L1 expression in the tumor tissue and other clinical factors. While it has the potential to activate the immune system against cancer, it can also cause immune-related adverse events that require close monitoring and management Pembrolizumab Immunotherapy Agent Essay Discussion Paper

This question has already been tackled by one of our writers and a good grade recorded. You can equally get high grades by simply making your order for this or any other school assignment that you may have.

Every Student Buys Essays from us, here is why!

Pressed for time to complete assignments or when you feel like you cannot write, you can purchase an essay on our website. Some students also want model papers to use as samples when revising or writing. There are also students who approach our essay writing service to beat deadlines. We handle every type of homework, assignment, and academic writing tasks. You can buy college essays and other assignments here. At a glance, here are some reasons students prefer our website.

100% Original Essays and Papers

You can be sure that you are getting a paper that is custom written based on your instructions. We do not sell papers that are pre-written. Instead, we write every essay from scratch. When you say “write my essay,” we respond by giving you a paper that is 100% original and free of any plagiarism. The essays you purchase from us have never been sold anywhere.

Flexible & Affordable Prices

It does not cost a fortune to get academic writing help on our website. If you have a question from class, place an order, get a discount, and get cheap essay writing services. What you see as the price is what you pay for. There are no any hidden charges. If you need urgent papers, they might cost a little more, but the price is worth the quality you get in the end. Hire a professional academic writer beginning from $13 a page.

Anonymity, Privacy, and Confidentiality

No one will ever know that you purchased an essay or assignment from our website. The essays you buy from us are written by experts. Your data is only used to coordinate the essay writing services you get. No one can access your personal information and data. Go ahead and order an essay from our website. It is safe, secure, and convenient.

Order a Unique Copy of this Assignment
275 Words

By placing an order you agree to our terms of service

Place Order »